Search
Watson Biotech Receives Approval for Clinical Trial Application of Respiratory Syncytial Virus mRNA Vaccine; No Such Vaccine Yet Approved in China
2 week ago /
Read about 0 minute
Author：小编
Watson Biotech, in partnership with Fudan University and Shanghai Blue Magpie Biomedical, has successfully submitted a clinical trial application for their jointly developed respiratory syncytial virus (RSV) mRNA vaccine to the National Medical Products Administration (NMPA). The application has been duly accepted. Leveraging its proprietary mRNA technology platform, this vaccine aims to prevent lower respiratory tract diseases caused by RSV. Despite the global availability of three similar vaccines, the development of this vaccine remains of utmost importance. The application is currently under review for approval to commence clinical trials and is not anticipated to significantly impact the company's performance this year.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
